790 related articles for article (PubMed ID: 17934985)
1. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
[TBL] [Abstract][Full Text] [Related]
2. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival.
Varenhorst E; Garmo H; Holmberg L; Adolfsson J; Damber JE; Hellström M; Hugosson J; Lundgren R; Stattin P; Törnblom M; Johansson JE
Scand J Urol Nephrol; 2005; 39(2):117-23. PubMed ID: 16019764
[TBL] [Abstract][Full Text] [Related]
3. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
[TBL] [Abstract][Full Text] [Related]
4. Population-based study of prostate-specific antigen testing and prostate cancer detection in clinical practice in northern Sweden.
Pilebro B; Johansson R; Damber L; Damber JE; Stattin P
Scand J Urol Nephrol; 2003; 37(3):210-2. PubMed ID: 12775278
[TBL] [Abstract][Full Text] [Related]
5. Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry.
Stattin P; Johansson R; Damber JE; Hellström M; Hugosson J; Lundgren R; Varenhorst E; Johansson JE
Scand J Urol Nephrol; 2003; 37(6):461-5. PubMed ID: 14675917
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen as surrogate for characterizing prostate cancer subgroups.
Sandblom G; Holmberg L; Damber JE; Hugosson J; Johansson JE; Lundgren R; Mattsson E; Nilsson J; Varenhorst E
Scand J Urol Nephrol; 2002; 36(2):106-12. PubMed ID: 12028683
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden.
Bratt O; Berglund A; Adolfsson J; Johansson JE; Törnblom M; Stattin P;
Scand J Urol Nephrol; 2010 Dec; 44(6):384-90. PubMed ID: 20624113
[TBL] [Abstract][Full Text] [Related]
8. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates.
Bratt O; Garmo H; Adolfsson J; Bill-Axelson A; Holmberg L; Lambe M; Stattin P
J Natl Cancer Inst; 2010 Sep; 102(17):1336-43. PubMed ID: 20724726
[TBL] [Abstract][Full Text] [Related]
9. Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.
Tonita JM; Skarsgard D; Muhajarine N
Cancer Causes Control; 2009 Mar; 20(2):201-9. PubMed ID: 18825504
[TBL] [Abstract][Full Text] [Related]
10. [Observational survey on variations of prostate cancer incidence by stage in the Nord-Pas-de-Calais region between 1998 and 2004].
Flamand V; Zini L; Salleron J; Fantoni JC; Biserte J; Villers A
Prog Urol; 2008 Jan; 18(1):53-9. PubMed ID: 18342157
[TBL] [Abstract][Full Text] [Related]
11. Geographical variation in incidence of prostate cancer in Sweden.
Stattin P; Johansson R; Lodnert R; Andrén O; Bill-Axelsson A; Bratt O; Damber JE; Hellström M; Hugosson J; Lundgren R; Törnblom M; Varenhorst E; Johansson JE
Scand J Urol Nephrol; 2005; 39(5):372-9. PubMed ID: 16257838
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen velocity in untreated, localized prostate cancer.
Venkitaraman R; Norman A; Woode-Amissah R; Dearnaley D; Horwich A; Huddart R; Parker C
BJU Int; 2008 Jan; 101(2):161-4. PubMed ID: 17850368
[TBL] [Abstract][Full Text] [Related]
13. The impact of prostate-specific antigen level at diagnosis on the relative survival of 28,531 men with localized carcinoma of the prostate.
Sandblom G; Ladjevardi S; Garmo H; Varenhorst E
Cancer; 2008 Feb; 112(4):813-9. PubMed ID: 18098207
[TBL] [Abstract][Full Text] [Related]
14. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.
Akre O; Garmo H; Adolfsson J; Lambe M; Bratt O; Stattin P
Eur Urol; 2011 Sep; 60(3):554-63. PubMed ID: 21664039
[TBL] [Abstract][Full Text] [Related]
15. [A clinical analysis of patients with early-stage prostate cancer managed without initial treatment].
Kawa G; Hiura Y; Satoh H; Sugi M; Fujita I; Oguchi N; Doi H; Ashida M; Okada H; Muguruma K; Murota T; Koyama Y; Kawamura H; Ohara T; Kawakita M; Matsuda T
Hinyokika Kiyo; 2002 Mar; 48(3):133-8. PubMed ID: 11993205
[TBL] [Abstract][Full Text] [Related]
16. Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden.
Stattin P; Holmberg E; Bratt O; Adolfsson J; Johansson JE; Hugosson J;
J Urol; 2008 Dec; 180(6):2423-9; discussion 2429-30. PubMed ID: 18930283
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of prostate cancer in Japanese men in the eras before and after serum prostate-specific antigen testing.
Okihara K; Nakanishi H; Nakamura T; Mizutani Y; Kawauchi A; Miki T
Int J Urol; 2005 Jul; 12(7):662-7. PubMed ID: 16045559
[TBL] [Abstract][Full Text] [Related]
18. Active surveillance for the management of prostate cancer in a contemporary cohort.
Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
[TBL] [Abstract][Full Text] [Related]
19. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.
Mokete M; Shackley DC; Betts CD; O'Flynn KJ; Clarke NW
BJU Int; 2006 Feb; 97(2):266-9. PubMed ID: 16430626
[TBL] [Abstract][Full Text] [Related]
20. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.
Berger AP; Deibl M; Strasak A; Bektic J; Pelzer AE; Klocker H; Steiner H; Fritsche G; Bartsch G; Horninger W
Urology; 2007 Jan; 69(1):134-8. PubMed ID: 17270635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]